MRM vs MNMD

MEDIROM Healthcare Technologies Inc.

(MRM) offers the better valuation at 6. 4x trailing P/E, making it the more compelling value choice. Analysts rate Mind Medicine (MindMed) Inc. (MNMD) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Mind Medicine (MindMed) Inc.

(MNMD) delivered a total return of -57. 9%, compared to -88. 2% for MEDIROM Healthcare Technologies Inc. (MRM). Over 10 years, the gap is even starker: MNMD returned +512. 1% versus MRM's -92. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), MEDIROM Healthcare Technologies Inc.

(MRM) is the lower-risk stock at -0. 54β versus Mind Medicine (MindMed) Inc. 's 1. 68β — meaning MNMD is approximately -410% more volatile than MRM relative to the S&P 500.

On earnings-per-share growth, the picture is similar: MEDIROM Healthcare Technologies Inc.

grew EPS 28. 1% year-over-year, compared to -1273. 3% for Mind Medicine (MindMed) Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

MEDIROM Healthcare Technologies Inc.

(MRM) is the more profitable company, earning 1. 8% net margin versus 0. 0% for Mind Medicine (MindMed) Inc. — meaning it keeps 1. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MNMD leads at 0. 0% versus -0. 2% for MRM. At the gross margin level — before operating expenses — MRM leads at 27. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, MEDIROM Healthcare Technologies Inc.

(MRM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 54)). Mind Medicine (MindMed) Inc. (MNMD) carries a higher beta of 1. 68 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MRM: -92. 3%, MNMD: +512. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MRM (Consumer Cyclical) and MNMD (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MRM is a small-cap high-growth stock; MNMD is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.